Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are a specific class of drugs originally developed for treating type 2 diabetes mellitus. Subsequently, studies demonstrated that their action was not limited to glycemic control but could also have positive effects on other specific outcomes, parti...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/3/720 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849342832085565440 |
|---|---|
| author | Nicia I. Profili Roberto Castelli Roberto Manetti Marta C. Sircana Michela Pagni Gemma Lisa Sechi Antonio Gidaro Costantino Cossu Francesco Bella Alessandro P. Delitala |
| author_facet | Nicia I. Profili Roberto Castelli Roberto Manetti Marta C. Sircana Michela Pagni Gemma Lisa Sechi Antonio Gidaro Costantino Cossu Francesco Bella Alessandro P. Delitala |
| author_sort | Nicia I. Profili |
| collection | DOAJ |
| description | Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are a specific class of drugs originally developed for treating type 2 diabetes mellitus. Subsequently, studies demonstrated that their action was not limited to glycemic control but could also have positive effects on other specific outcomes, particularly at the cardiovascular level. Indeed, due to their diuretic effect, SGLT2i improve the clinical control of chronic heart failure and reduce the risk of rehospitalization. In addition, other studies reported a protective effect on major cardiovascular events and mortality. More recently, it has been suggested that the prescription of SGLT2i after an acute myocardial infarction may have positive effects due to their possible effect on inflammation, arrhythmias, and ventricular remodeling. Here, we reviewed studies focused on SGLT2i after an acute myocardial infarction in patients treated with percutaneous coronary intervention. |
| format | Article |
| id | doaj-art-2f9e3cf9f6c4411398f98c162d12e696 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-2f9e3cf9f6c4411398f98c162d12e6962025-08-20T03:43:15ZengMDPI AGBiomedicines2227-90592025-03-0113372010.3390/biomedicines13030720Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial InfarctionNicia I. Profili0Roberto Castelli1Roberto Manetti2Marta C. Sircana3Michela Pagni4Gemma Lisa Sechi5Antonio Gidaro6Costantino Cossu7Francesco Bella8Alessandro P. Delitala9Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, ItalyDepartment of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, ItalyDepartment of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, ItalyDepartment of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, ItalyDepartment of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, ItalyDepartment of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, ItalyDepartment of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Luigi Sacco Hospital, 20157 Milan, ItalyAzienda Ospedaliero-Universitaria di Sassari, 07100 Sassari, ItalyAzienda Ospedaliero-Universitaria di Sassari, 07100 Sassari, ItalyDepartment of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, ItalySodium–glucose cotransporter-2 inhibitors (SGLT2i) are a specific class of drugs originally developed for treating type 2 diabetes mellitus. Subsequently, studies demonstrated that their action was not limited to glycemic control but could also have positive effects on other specific outcomes, particularly at the cardiovascular level. Indeed, due to their diuretic effect, SGLT2i improve the clinical control of chronic heart failure and reduce the risk of rehospitalization. In addition, other studies reported a protective effect on major cardiovascular events and mortality. More recently, it has been suggested that the prescription of SGLT2i after an acute myocardial infarction may have positive effects due to their possible effect on inflammation, arrhythmias, and ventricular remodeling. Here, we reviewed studies focused on SGLT2i after an acute myocardial infarction in patients treated with percutaneous coronary intervention.https://www.mdpi.com/2227-9059/13/3/720SGLT2isodium–glucose cotransporter-2 inhibitorsacute myocardial infarctionacute heart failurediabetescardiovascular disease |
| spellingShingle | Nicia I. Profili Roberto Castelli Roberto Manetti Marta C. Sircana Michela Pagni Gemma Lisa Sechi Antonio Gidaro Costantino Cossu Francesco Bella Alessandro P. Delitala Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction Biomedicines SGLT2i sodium–glucose cotransporter-2 inhibitors acute myocardial infarction acute heart failure diabetes cardiovascular disease |
| title | Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction |
| title_full | Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction |
| title_fullStr | Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction |
| title_full_unstemmed | Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction |
| title_short | Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction |
| title_sort | sodium glucose cotransporter 2 inhibitors after acute myocardial infarction |
| topic | SGLT2i sodium–glucose cotransporter-2 inhibitors acute myocardial infarction acute heart failure diabetes cardiovascular disease |
| url | https://www.mdpi.com/2227-9059/13/3/720 |
| work_keys_str_mv | AT niciaiprofili sodiumglucosecotransporter2inhibitorsafteracutemyocardialinfarction AT robertocastelli sodiumglucosecotransporter2inhibitorsafteracutemyocardialinfarction AT robertomanetti sodiumglucosecotransporter2inhibitorsafteracutemyocardialinfarction AT martacsircana sodiumglucosecotransporter2inhibitorsafteracutemyocardialinfarction AT michelapagni sodiumglucosecotransporter2inhibitorsafteracutemyocardialinfarction AT gemmalisasechi sodiumglucosecotransporter2inhibitorsafteracutemyocardialinfarction AT antoniogidaro sodiumglucosecotransporter2inhibitorsafteracutemyocardialinfarction AT costantinocossu sodiumglucosecotransporter2inhibitorsafteracutemyocardialinfarction AT francescobella sodiumglucosecotransporter2inhibitorsafteracutemyocardialinfarction AT alessandropdelitala sodiumglucosecotransporter2inhibitorsafteracutemyocardialinfarction |